CCR5 signaling is not high in primary breast cancer tumor sites, but is upregulated in secondary sites of metastasis, which suggests the CCR5-CCL5 axis may play a role in upregulating circulating tumor cells (CTC), and thereby contribute to a poor clinical outcome [55,64,70,71]. This evidence concerns the gene CCR5 and neoplasm.